SCHEMBL5043783

SCHEMBL5043783

COc1ccc(-c2nc(-c3cc(C(=O)O)c(C)n3Cc3cccs3)cs2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.50
MAPT P10636 3/20 0.50
HSD17B10 Q99714 3/20 0.50
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
TSHR P16473 2/20 0.50
MAPK1 P28482 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
ESR1 P03372 1/20 0.50
KDM4E B2RXH2 3/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
EIF4E P06730 5/20 0.47
POLB P06746 2/20 0.44
USP2 O75604 3/20 0.43
CYP2C9 P11712 3/20 0.43
CASP1 P29466 3/20 0.43
CASP7 P55210 3/20 0.43
HIF1A Q16665 3/20 0.43
CYP1A2 P05177 2/20 0.43
HPGD P15428 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6879060 0.89 KDM4E (0.53) ALDH1A1MAPTNPC1RAB9AKDM4E
SCHEMBL5045711 0.89 KDM4E (0.55) ALDH1A1MAPTNPC1RAB9AKDM4E
SCHEMBL5043336 0.88 NPC1 (0.50) ALDH1A1MAPTHSD17B10NPC1RAB9A
SCHEMBL5039266 0.87 NPC1 (0.51) ALDH1A1MAPTHSD17B10NPC1RAB9A
SCHEMBL6471925 0.87 KDM4E (0.53) ALDH1A1MAPTNPC1RAB9AKDM4E
SCHEMBL5039868 0.86 ALDH1A1 (0.48) ALDH1A1MAPTHSD17B10NPC1RAB9A
SCHEMBL6883228 0.86 EIF4E (0.50) ALDH1A1MAPTNPC1RAB9AKDM4E
SCHEMBL6882640 0.86 KDM4E (0.52) ALDH1A1MAPTNPC1RAB9AKDM4E
SCHEMBL5048654 0.86 MAPT (0.50) ALDH1A1MAPTHSD17B10NPC1RAB9A
SCHEMBL5044878 0.86 MAPT (0.52) ALDH1A1MAPTHSD17B10NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1583762-B1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS HOFFMANN LA ROCHE (CH) 2008-07-09 EP disclosed
US-7135488-B2 Pyrrolyl-thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2006-11-14 US disclosed
EP-1583762-A1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2005-10-12 EP disclosed
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives HOFFMAN-LA ROCHE INC. 2004-07-29 US disclosed
WO-2004060888-A1 NOVEL CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives CNR1, CNR2, NPY1R ALDH1A1 959/4885MAPT 3334/4885HSD17B10 2802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.